Nyxoah (NASDAQ:NYXH) Price Target Cut to $15.00 by Analysts at Stifel Nicolaus

Nyxoah (NASDAQ:NYXH) had its price objective reduced by Stifel Nicolaus from $16.00 to $15.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Nyxoah in a report on Friday, December 13th.

Nyxoah Price Performance

Shares of Nyxoah stock opened at $10.51 on Friday. Nyxoah has a twelve month low of $6.76 and a twelve month high of $20.00. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The company has a 50-day simple moving average of $10.29 and a two-hundred day simple moving average of $9.18. The stock has a market capitalization of $357.97 million, a price-to-earnings ratio of -5.62 and a beta of 1.42.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Thursday, March 13th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. Analysts forecast that Nyxoah will post -1.91 EPS for the current year.

Institutional Investors Weigh In On Nyxoah

Several hedge funds and other institutional investors have recently made changes to their positions in NYXH. Kovack Advisors Inc. bought a new stake in shares of Nyxoah during the 3rd quarter valued at approximately $96,000. LPL Financial LLC bought a new stake in shares of Nyxoah during the 4th quarter valued at approximately $102,000. Walleye Capital LLC grew its holdings in shares of Nyxoah by 23.9% during the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock valued at $119,000 after purchasing an additional 2,862 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in shares of Nyxoah during the 4th quarter valued at approximately $135,000. Finally, Geode Capital Management LLC grew its holdings in shares of Nyxoah by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after purchasing an additional 2,774 shares during the last quarter.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.